ClinicalTrials.gg
CompletedNCT04186845Updated Sep 22, 2025Results posted

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

A Phase 3 interventional study of rhPSMA-7.3 (18F) Injection and Positron emission tomography scan in Prostate Cancer, sponsored by Blue Earth Diagnostics. Completed at 28 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
391
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms — 6 open to participants now, 7 under way, 2 of them phase 3. flotufolastat F 18 · Prostatic Neoplasms.

Enrollment
Largest of 15
391 · median 70
Started
2020
with 1 other
Phase 3
4 of 15
1 open now
Registered
2nd of 15
by date
Lead sponsor
4 of 15
Blue Earth Diagnostics

Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, this one has the largest enrollment, is one of 2 that started in 2020, is one of 4 in phase 3, and was the 2nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About flotufolastat F 18

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA) following prior therapy.

Read the detailed description

The primary objective of this study was to assess the patient-level correct detection rate (CDR) and region-level positive predictive value (PPV) of rhPSMA-7.3 (18F) positron emission tomography (PET) for biochemical recurrence (BCR) of prostate cancer using histopathology or imaging as a standard of truth (SoT).

03

Conditions studied

  • Prostate Cancer

Keywords

  • Recurrent Prostate Cancer
  • Diagnostic
  • Prostate Specific Membrane Antigen (PSMA)
  • Positron Emission Tomography (PET) Scan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is male and aged >18 years old.
  2. History of localized adenocarcinoma of the prostate with prior curative intent treatment.
  3. An elevated PSA, clinically suspicious for biochemically recurrent disease:

    • Following Radical Prostatectomy: PSA >0.2 ng/mL
    • Following Radiotherapy: nadir +2 ng/mL.
  4. Potentially eligible for salvage therapy with curative intent.

Exclusion criteria

Exclusion Criteria:

  1. Patients who are planned to have an x-ray contrast agent or other PET radiotracer \<24 hours prior to the PET scan.
  2. Patients currently receiving Androgen Deprivation Therapy (ADT).
05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
391 participants (actual)

Study arms

  • Experimental
    Patients

    Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan

    Drug: rhPSMA-7.3 (18F) Injection · Diagnostic Test: Positron emission tomography scan

Interventions

  • Radioligand for PET CT scanning

    Also known as: flotufolastat F18

  • Diagnostic testPositron emission tomography scan

    Imaging scan with radioligand

    Also known as: PET scan

06

What researchers measure

Primary outcomes

  1. Patient-level CDR and Region-level PPV of rhPSMA7.3 (18F) PET for BCR of Prostate Cancer Using Histopathology or Imaging as a SoT

    The CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any coexisting FP findings. When determining the region-level PPV, all rhPSMA7.3 (18F) PET-positive regions (maximum of three per patient) were categorized as TP or FP regions using histopathology or imaging.

    Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan

Secondary outcomes

  1. Patient-level CDR and Region-level PPV of rhPSMA-7.3 (18F) PET in Patients Who Had Negative Baseline Conventional Imaging

    Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.

    Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan

  2. Patient-level CDR and Region-level PPV of rhPSMA-7.3 (18F) PET for Recurrence in Those Patients With and Without Reference Standard Histopathology Available

    Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.

    Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan

  3. Patient-level CDR of rhPSMA-7.3 (18F) PET Stratified by PSA Level

    Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The last PSA level before the PET scan will be used to stratify the patients

    Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan

  4. CDR of rhPSMA-7.3 (18F) PET in the Following Regions: Prostate/Prostate Bed, Pelvic Lymph Nodes, Other

    Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The analysis was performed for each region and for each of the blinded independent readers

    Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan

  5. Percentage of Patients in Whom rhPSMA-7.3 (18F) PET Imaging Results Changed the Intended Patient Management (Major and Other Changes)

    This analysis used patients in the EAP who had documented patient management plans in the EDC before and after the rhPSMA-7.3 (18F) PET scan

    Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan

  6. Reader Kappa Statistics of rhPSMA7.3 (18F) Scan Interpretation by the Blinded Independent Readers

    The Cohen's kappa statistic will be calculated to assess pairwise agreement between any 2 blinded independent readers

    Time frame: PET Scan on Day 1

  7. Region-level PPV of rhPSMA-7.3 (18F) PET Stratified by PSA Level

    Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.. The last PSA level before the rhPSMA-7.3 (18F) PET scan was used to stratify patients.

    Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan

  8. Region-level PPV of rhPSMA-7.3 (18F) PET for Recurrence in Those Patients With and Without Reference Standard Histopathology Available

    Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions. The data are analysed by whether the patients have had histopathology as reference standard.

    Time frame: Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan

07

Results

Posted Feb 26, 2025

Participant flow

This study was conducted from 04 May 20 (first patient, screening visit) and 12 Oct 21 (database lock), with last patient, last visit on 28 Apr 21. It was conducted at 28 activated study sites (27 recruited) in 3 countries. Of the 420 patients screened, 391 patients met all the study eligibility criteria

Participant flow — Overall Study
MilestoneSingle Arm
Started391
Completed378
Not completed13
Withdrew: Death2
Withdrew: Lost to follow-up1
Withdrew: Physician decision1
Withdrew: Protocol violation1
Withdrew: Biopsy ordered but area too small to biopsy1
Withdrew: Biopsy ordered but not done1
Withdrew: It was previously confirmed1
Withdrew: Patient cancelled scheduled scans2
Withdrew: Psma pet/ct scan show disease within previously bx area1
Withdrew: Subject refused confirmatory imaging1
Withdrew: Too small to biopsy1

Outcome measures

PrimaryPatient-level CDR and Region-level PPV of rhPSMA7.3 (18F) PET for BCR of Prostate Cancer Using Histopathology or Imaging as a SoT

The CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any coexisting FP findings. When determining the region-level PPV, all rhPSMA7.3 (18F) PET-positive regions (maximum of three per patient) were categorized as TP or FP regions using histopathology or imaging.

Time frame:
Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Reported as:
Number · percentage
Patient-level CDR and Region-level PPV of rhPSMA7.3 (18F) PET for BCR of Prostate Cancer Using Histopathology or Imaging as a SoT
percentageEfficacy Analysis Population (EAP)
Patient-level CDR - Central Reader 154.1 (48.8 to 59.3)
Patient-level CDR - Central Reader 251.4 (46.1 to 56.6)
Patient-level CDR - Central Reader 351.6 (46.4 to 56.9)
Region-level PPV - Central Reader 146.2 (42.0 to 50.3)
Region-level PPV - Central Reader 260.3 (55.1 to 65.5)
Region-level PPV - Central Reader 352.6 (47.6 to 57.5)
SecondaryPatient-level CDR and Region-level PPV of rhPSMA-7.3 (18F) PET in Patients Who Had Negative Baseline Conventional Imaging

Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.

Time frame:
Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Reported as:
Number · percentage
Patient-level CDR and Region-level PPV of rhPSMA-7.3 (18F) PET in Patients Who Had Negative Baseline Conventional Imaging
percentageEfficacy Analysis Population (EAP)
Patient Level CDR - Central Reader 146.8 (40.5 to 53.2)
Patient Level CDR - Central Reader 245.2 (38.9 to 51.6)
Patient Level CDR - Central Reader 345.6 (39.3 to 52.0)
Region-level PPV - Central Reader 139.7 (34.6 to 44.9)
Region-level PPV - Central Reader 256.2 (49.6 to 62.7)
Region-level PPV - Central Reader 346.8 (40.7 to 52.9)
SecondaryPatient-level CDR and Region-level PPV of rhPSMA-7.3 (18F) PET for Recurrence in Those Patients With and Without Reference Standard Histopathology Available

Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.

Time frame:
Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Reported as:
Number · percentage
Patient-level CDR and Region-level PPV of rhPSMA-7.3 (18F) PET for Recurrence in Those Patients With and Without Reference Standard Histopathology Available
percentageHistopathology Available as SoTHistopathology Not Available as SoT
Patient-level CDR - Central Reader 175.4 (63.5 to 84.9)49.2 (43.3 to 55.0)
Patient-level CDR - Central Reader 276.8 (65.1 to 86.1)45.5 (39.7 to 51.3)
Patient-level CDR - Central Reader 373.9 (61.9 to 89.7)46.5 (40.7 to 52.3)
Region-level PPV - Central Reader 160.9 (52.0 to 69.8)42.4 (37.7 to 47.0)
Region-level PPV - Central Reader 267.0 (57.6 to 76.4)57.9 (51.7 to 64.0)
Region-level PPV - Central Reader 362.6 (53.5 to 71.8)49.5 (43.8 to 55.3)
SecondaryPatient-level CDR of rhPSMA-7.3 (18F) PET Stratified by PSA Level

Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The last PSA level before the PET scan will be used to stratify the patients

Time frame:
Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Reported as:
Number · percentage
Patient-level CDR of rhPSMA-7.3 (18F) PET Stratified by PSA Level
percentagePSA<0.50.5≤PSA<1.01.0≤PSA<2.02.0≤PSA<5.05.0≤PSA<10.0PSA≥10.0
Central Reader 129.5 (21.0 to 39.2)44.4 (31.9 to 57.5)65.1 (49.1 to 79.0)72.7 (62.2 to 81.7)61.1 (43.5 to 76.9)80.7 (62.5 to 92.5)
Central Reader 223.8 (16.0 to 33.1)41.3 (29.0 to 54.4)65.1 (49.1 to 79.0)70.5 (59.8 to 79.7)58.3 (40.8 to 74.5)83.9 (66.3 to 94.5)
Central Reader 325.7 (17.7 to 35.2)46.0 (33.4 to 59.1)62.8 (46.7 to 77.0)69.3 (58.6 to 78.7)58.3 (40.8 to 74.5)77.4 (58.9 to 90.4)
SecondaryCDR of rhPSMA-7.3 (18F) PET in the Following Regions: Prostate/Prostate Bed, Pelvic Lymph Nodes, Other

Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The analysis was performed for each region and for each of the blinded independent readers

Time frame:
Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Reported as:
Number · percentage
CDR of rhPSMA-7.3 (18F) PET in the Following Regions: Prostate/Prostate Bed, Pelvic Lymph Nodes, Other
percentageProstate/ Prostate BedPelvic Lymph NodesOther (Extra-pelvic) Sites
Central Reader 116.7 (13.0 to 20.9)21.6 (17.5 to 26.2)29.2 (24.6 to 34.2)
Central Reader 213.1 (9.8 to 17.0)19.4 (15.5 to 23.8)30.6 (25.9 to 35.6)
Central Reader 313.7 (10.3 to 17.6)22.4 (18.2 to 27.0)25.7 (21.3 to 30.5)
SecondaryPercentage of Patients in Whom rhPSMA-7.3 (18F) PET Imaging Results Changed the Intended Patient Management (Major and Other Changes)

This analysis used patients in the EAP who had documented patient management plans in the EDC before and after the rhPSMA-7.3 (18F) PET scan

Time frame:
Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Reported as:
Number · percentage
Percentage of Patients in Whom rhPSMA-7.3 (18F) PET Imaging Results Changed the Intended Patient Management (Major and Other Changes)
percentageChange in Management Plan
No Change6.6
Major Change46.7
Minor Change4.8
Additional Information Required31.7
Pre-PSMA Plan Not Valid10.2
SecondaryReader Kappa Statistics of rhPSMA7.3 (18F) Scan Interpretation by the Blinded Independent Readers

The Cohen's kappa statistic will be calculated to assess pairwise agreement between any 2 blinded independent readers

Time frame:
PET Scan on Day 1
Reported as:
Number · percentage
Reader Kappa Statistics of rhPSMA7.3 (18F) Scan Interpretation by the Blinded Independent Readers
percentagePatient-level Inter-reader Reproducibility
Central Reader 1 vs Reader 20.29 (0.21 to 0.38)
Central Reader 1 vs Reader 30.38 (0.25 to 0.51)
Central Reader 2 vs Reader 30.50 (0.41 to 0.60)
SecondaryRegion-level PPV of rhPSMA-7.3 (18F) PET Stratified by PSA Level

Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.. The last PSA level before the rhPSMA-7.3 (18F) PET scan was used to stratify patients.

Time frame:
Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Reported as:
Number · percentage
Region-level PPV of rhPSMA-7.3 (18F) PET Stratified by PSA Level
percentagePSA <0.50.5≤PSA<1.01.0≤PSA<2.02.0≤PSA<5.05.0≤PSA<10.0PSA≥10.0
Central Reader 129.1 (20.5 to 37.7)37.1 (27.6 to 46.6)45.6 (35.1 to 56.1)57.7 (50.1 to 65.3)57.9 (44.9 to 70.9)59.6 (47.6 to 71.7)
Central Reader 250.8 (36.9 to 64.8)51.8 (38.9 to 64.6)57.4 (43.7 to 71.1)65.0 (55.3 to 74.6)71.7 (56.8 to 86.7)62.7 (50.6 to 74.9)
Central Reader 334.5 (24.0 to 45.0)45.1 (33.5 to 56.7)52.5 (38.7 to 66.2)64.9 (55.9 to 73.9)58.7 (41.5 to 75.9)60.8 (47.3 to 74.2)
SecondaryRegion-level PPV of rhPSMA-7.3 (18F) PET for Recurrence in Those Patients With and Without Reference Standard Histopathology Available

Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions. The data are analysed by whether the patients have had histopathology as reference standard.

Time frame:
Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan
Reported as:
Number · percentage
Region-level PPV of rhPSMA-7.3 (18F) PET for Recurrence in Those Patients With and Without Reference Standard Histopathology Available
percentageHistopathology Available as SoTHistopathology Not Available as SoT
Central Reader 160.9 (52.0 to 69.8)42.4 (37.7 to 47.0)
Central Reader 267.0 (57.6 to 76.4)57.9 (51.7 to 64.0)
Central Reader 362.6 (53.5 to 71.8)49.5 (43.8 to 55.3)

Adverse events

Collected over AEs were also monitored throughout the study through study completion, an average of 90 days post-IMP administration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm2/391 (0.5%)2/391 (0.5%)28/391 (7.2%)
Most frequent serious events
Most frequent serious events
EventSingle Arm
Sudden deathGeneral disorders1/391
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/391
Most frequent other events
Showing 10 of 20
Most frequent other events
EventSingle Arm
HypertensionVascular disorders7/391
DiarrheaGastrointestinal disorders4/391
Injection site reactionGeneral disorders2/391
HeadacheNervous system disorders2/391
FlushingVascular disorders1/391
Injection site discomfortGeneral disorders1/391
FatigueGeneral disorders1/391
Sinus congestionRespiratory, thoracic and mediastinal disorders1/391
AnxietyPsychiatric disorders1/391
TachycardiaCardiac disorders1/391

Baseline characteristics

All patients who were scheduled to receive the rhPSMA-7.3 (18F) injection having met the inclusion/exclusion criteria or who received the rhPSMA-7.3 (18F) injection.

Age, Categorical
Age, Categorical(Participants)Single Arm
<=18 years0
Between 18 and 65 years121
>=65 years270
Age, Continuous
Age, Continuous(years)Single Arm
Mean68.3 ± 7.92
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm
Female0
Male391
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single Arm
Hispanic or Latino18
Not Hispanic or Latino342
Unknown or Not Reported31
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Single Arm
Black or African American61
White295
Other14
Not Reported21
Region of Enrollment
Region of Enrollment(participants)Single Arm
Netherlands9
United States375
Finland7
Total Gleason Score
Total Gleason Score(participants)Single Arm
≤639
=7232
=841
=963
=101
Missing15
Gleason Grade Group (GGG)
Gleason Grade Group (GGG)(participants)Single Arm
=139
=2104
=3116
=441
=564
Missing27

9 further baseline measures are reported on the registry.

08

Study locations

28 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Tower Urology
    Los Angeles, California 90048, United States
  • University of California Irvine Medical Center (UCIMC)
    Orange, California 92868, United States
  • John Wayne Cancer Institute
    Santa Monica, California 90403, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Northside Hospital
    Austell, Georgia 30342, United States
  • Northshore University HealthSystem
    Evanston, Illinois 60201, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Chesapeake Urology Research Associates
    Towson, Maryland 21204, United States
  • University of Michigan Ann Arbor
    Ann Arbor, Michigan 48109, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Queens Hospital Center (QHC - Queens Cancer Center
    Jamaica, New York 11432, United States
  • Mount Sinai Faculty Practice Associates
    New York, New York 10029, United States
  • Stony Brook University
    Stony Brook, New York 11794, United States
  • Montefiore Hospital
    The Bronx, New York 10461, United States
  • Duke University Medical Center
    Durham, North Carolina 27701, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • MidLantic Urology
    Philadelphia, Pennsylvania 19004, United States
  • MD Anderson Hospital
    Houston, Texas 77054, United States
  • Urology San Antonio
    San Antonio, Texas 78229, United States
  • University of Virginia - Health Science Center
    Charlottesville, Virginia 22908, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Turku University Hospital
    Turku, FI-20520, Finland
  • CWZ
    Nijmegen, 6532, Netherlands
  • Maxima MC
    Veldhoven, 5504 DB, Netherlands
09

References and documents

Publications

  • Fleming MT, Hermsen R, Purysko AS, Chau A, Davis P, Chapin BF, Schuster DM. True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study. J Nucl Med. 2024 Jul 1;65(7):1080-1086. doi: 10.2967/jnumed.123.267271. PubMed 38782456 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Apr 2021, 11 months.

Results were first posted in Feb 2025, 3 years 9 months after primary completion. A results delay was requested in Mar 2022.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 11 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2019
First posted
Dec 5, 2019
StartActual
May 4, 2020
Primary completionActual
Apr 28, 2021
CompletionActual
Apr 28, 2021
Results delay requested
Mar 15, 2022
Results first posted
Feb 26, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04186845
Collaborators
Parexel
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
May 4, 2020
Primary completion
Apr 28, 2021
Completion
Apr 28, 2021
Results posted
Feb 26, 2025
Last update
Sep 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flotufolastat F 18

Start the discussion